Plasma Clusterin Levels and the rs11136000 Genotype in Individuals with Mild Cognitive Impairment and Alzheimer’s Disease

Abstract

This study examined control, MCI and AD subjects, identifying for the first time that plasma clusterin levels were influenced, not only by the presence of AD, but also the transitional stage of MCI, while rs11136000 genotype only influenced plasma clusterin levels in the control group. The increase in plasma clusterin in MCI and AD subjects may occur in response to the disease process and would be predicted to increase binding capacity for amyloid-beta peptides in plasma, enhancing their removal from the brain.

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging

“…These findings were consistent with some of the earlier studies [10,11,22]. Thambisetty et al [9], 2012, showed a correlation of plasma apoJ concentration with the longitudinal atrophy changes in several regions of the brain in the MCI group.…”

“…Thambisetty et al [10], 2010, showed increased apoJ messenger RNA in the blood of AD patients, but there was no change in gene or protein expression of apoJ due to variation in the gene single nucleotide polymorphisms (SNPs). Mullan et al [22] showed that plasma apoJ levels were not only higher in MCI and AD compared with controls but MCI stage subjects had even higher levels compared with AD indicating that increase in plasma apoJ levels may occur as a response to the disease process. Differences in assaying techniques used (mass spectrometry based vs. ELISA) and varying blood collection protocols (fasting vs. nonfasting) may have contributed to the contradictory results obtained in some of the earlier studies [12,13].…”

Complement Biomarkers as Predictors of Disease Progression in Alzheimer’s Disease

“…for AD that is replicated across different assay platforms. In light of this, it is somewhat paradoxical that two disease-associated SNP in clusterin are reported to associate with decreased plasma levels[29,30].…”

Plasma and platelet clusterin ratio is altered in Alzheimer's disease patients with distinct neuropsychiatric symptoms: findings from a pilot study

“…Although two most recent studies on plasma clusterin measures have identified higher levels of clusterin even in MCI (Thambisetty et al, 2010, Mullan et al, 2013 and further increase with severity of AD (Schrijvers et al, 2011), a community-based study failed to repeat these findings in presymptomatic AD subjects followed over 10-year period (IJsselstijn et al, 2011). The latter findings were confirmed recently in a cross-sectional study of several types of dementia, including AD (Silajdžić et al, 2012).…”

“…One of the explanations may lie within the extent of progression of the disease, with rapid progression AD having higher levels of plasma clusterin than the more slowly progressive disease (Thambisetty et al, 2010, Schrijvers et al, 2011. Two most recent studies on larger cohorts of subjects with mild cognitive impairment (MCI) also documented a strong negative correlation between clusterin plasma levels and cognitive impairment (Song et al, 2012, Mullan et al, 2013, with MCI subjects having higher clusterin plasma content (Mullan et al, 2013). On the other hand, genotype profile patterns support the view that variants of the clusterin (CLU) gene may be either predictive of better cognitive performance in older adults (Barral et al, 2012) or associated with more rapid cognitive decline (Sweet et al, 2012) even in asymptomatic individuals in presymptomatic stages of dementia (Thambisetty et al, 2013).…”